BioSpace News Archive

Twist Bioscience Corporation (NASDAQ: TWST), today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 4:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time.

Arsenal Biosciences, Inc., a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced that members of its senior management team are scheduled to participate in the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022.

Emmaus Life Sciences, Inc. announced that Yutaka Niihara, M.D., M.P.H, Chairman and Chief Executive Officer of Emmaus, will present a company overview at the H.C. Wainwright BioConnect Conference, being held virtually, January 10-13, 2021.

ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the paper entitled “Dose Limiting, Adverse Event Associated Bradycardia with β-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial” (William Abraham, et al) has been published in Heart Rhythm O2, a publication of the Hearth Rhythm Society.

Endymed Ltd, currently traded on Tel Aviv Stock Exchange, is pleased to announce the appointment of Dr. Ziv Karni as Expert Technology Advisor.

OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced positive results from the recent Phase 2 study of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D).

Viveve Medical, Inc., a medical technology company focused on women’s health, announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright BIOCONNECT Conference, January 10 - 13, 2022.

Genmab A/S (Nasdaq: GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies.

Privia Health Group, Inc. (Nasdaq: PRVA) announced that it will participate in the 40th Annual J.P. Morgan Healthcare Conference.